IR
Superintel
OverviewMarketsWatchlist
© 2026 IR SuperintelMethodologyContact

Attovia Therapeutics Inc (ATTO)

CUSIP: 04987L102 | NYSE | 3 institutional holders

Quarters

Q3 2026
CompareDetailedHistoricalFundsOptions13D/13GPeersTargetingTrading SummaryProfile

Beneficial Ownership — 13D / 13G

Full history →

5%+ stakes reported outside the quarterly cycle. A 13D is due within five business days of the event below, so these figures lead the holders table until the filer's next 13F catches up to them.

HolderShares% of ClassChangeEvent Datevs 13F
13DFrazier Life Sciences XI, L.P.
with Frazier Life Sciences Public Fund, L.P., Fhmlsp, L.P., Fhmlsp, L.L.C., +3 more
6,154,21313.5%New 5%+ stakeAug 6, 2026No 13F filer matched
13GDeep Track Capital, LP

Institutional Holders — Q3 2026

Sanofi1,082,855
2.9% of portfolio›$18.6M
Geode Capital Management, LLC206,176
0.0% of portfolio›$3.5M
Citigroup Inc1,237
0.0% of portfolio›$21.2K
StyleTurnoverLocationFiled
Sanofi
1,082,855$18.6M2.9%Deep ValueVery LowParis, India2026-11-05
Geode Capital Management, LLC
206,176$3.5M0.0%IndexVery LowBoston, MA2026-11-06
Citigroup Inc
1,237$21.2K0.0%CoreMediumNew York, NY2026-11-04
3,207,138
7.5%
New 5%+ stake
Aug 5, 2026
No 13F filer matched
13DFrazier Life Sciences XI, L.P.6,154,213
13.5% of class · Aug 6, 2026New 5%+ stake
with Frazier Life Sciences Public Fund, L.P., Fhmlsp, L.P., Fhmlsp, L.L.C., +3 more
No 13F filer matched
13GDeep Track Capital, LP3,207,138
7.5% of class · Aug 5, 2026New 5%+ stake
No 13F filer matched